VANI

Vivani Medical, Inc. (VANI) - Q3 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2025. Vivani Medical, Inc. is a clinical-stage biopharmaceutical company developing miniature, ultra long-acting subdermal drug implants using its proprietary NanoPortal technology. The company operates two segments: the Biopharm Division (primary focus) and the Neurostimulation Division (Cortigent, Inc., a subsidiary being spun off). Vivani has no product revenue and relies on equity financing to fund operations.

Key Financial Metrics

Note: Working Capital is calculated as Total Current Assets ($4,175) minus Total Current Liabilities ($6,830) as of Sept 30, 2025.

Material Changes vs. Prior Period

• Liquidity Deterioration: Cash and cash equivalents decreased by approximately $15.7 million from $19.7 million at year-end 2024 to $4.0 million (including restricted cash) at September 30, 2025. Working capital turned negative, dropping from $14.5 million to $(2.7) million.
• Increased Burn Rate: Net loss for the nine months ended September 30, 2025, increased by 15% compared to the same period in 2024, driven by higher R&D expenses in the Biopharm division.
• Financing Activity: The company raised approximately $2.6 million in net proceeds from private sales transactions during the nine months ended September 30, 2025, compared to $13.7 million in a registered direct offering in the prior year period.
• Asset Reduction: Total assets declined by $16.5 million year-over-year, primarily due to the drawdown of cash reserves.

Guidance, Outlook, and Risks

• Development Milestones: The company successfully completed enrollment in the LIBERATE-1 Phase 1 clinical trial for NPM-115 (exenatide implant) in Australia, with top-line data released in August 2025 showing a positive safety profile. Based on this, Vivani plans to prioritize NPM-139 (semaglutide implant), with Phase 1 initiation expected in the first half of 2026.
• Cortigent Spin-off: Vivani is proceeding with the spin-off of its neurostimulation subsidiary, Cortigent, Inc. A record date was set in September 2025 but withdrawn in October 2025 due to U.S. federal government shutdown delays. A new record date is expected soon.
• Liquidity Outlook: Management estimates current cash plus committed capital from three equity purchase agreements ($18.6 million total) will fund operations into 2027. However, the company explicitly states it expects to continue incurring operating losses and requires additional capital to continue as a going concern.
• Legal Contingencies:
  • Pixium Vision: A pending appeal in the Paris Court of Appeal regarding a terminated MOU. The company accrued $1.675 million for this matter in 2022. The appeal was struck out in October 2024 for failure to enforce a prior judgment; Vivani must request reinstatement within two years.
  • Oppenheimer & Co.: Litigation seeking $1.625 million in damages. The court dismissed all claims except for breach of contract in June 2025; discovery is ongoing.
• Risk Factors: Significant risks include the inability to raise additional capital, potential delays in clinical trials, and the impact of U.S. government shutdowns on FDA/SEC review processes.

Investor Verification Checklist

• Cash Runway: Verify the status of the $18.6 million in committed capital from equity purchase agreements and the timeline for tranche closings.
• Cortigent Spin-off Status: Confirm the new record date for the Cortigent spin-off and the impact of the recent government shutdown on the timeline.
• LIBERATE-1 Data: Review the full top-line data from the LIBERATE-1 trial to assess the viability of the NPM-139 program.
• Legal Exposure: Monitor the status of the Pixium appeal reinstatement and the Oppenheimer breach of contract discovery.
• Working Capital: Assess the sustainability of operations given the negative working capital position of $(2.7) million.